biotech

95992888

Why Lpath Could Rise 300%

Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes the price target upside is off the charts as well. ...
Read Full Story »
buy sell

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences Inc. (NASDAQ: GILD) may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance above and ...
Read Full Story »
Biotechnology word cloud

Who Bucked the Short Interest Trend in Biotech Stocks?

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many ...
Read Full Story »
Food and Drug Administration logo

FDA Keeps Driving Up Future Cost of Inhalable Insulin

MannKind Corp. (NASDAQ: MNKD) is suffering another setback from the U.S. Food & Drug Administration. While the FDA has been far from a friend to MannKind over the past few ...
Read Full Story »
DNA

Pancreatic Cancer Trial Enrollment Halt Damages Halozyme

Halozyme Therapeutics Inc. (NASDAQ: HALO) will need some therapeutics of its own, as are its shareholders. Its shares got pounded Friday morning on news of a temporary halt of its ...
Read Full Story »
Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
biotech

Amgen Faces Cool Reception Over GSK Pact Termination

Amgen Inc. (NASDAQ: AMGN) submitted an SEC Filing showing that, as of April 1, its Amgen Manufacturing Ltd. subsidiary and GlaxoSmithKline PLC (NYSE: GSK), via Glaxo Group Ltd., have terminated ...
Read Full Story »
Pills

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new research report, Jefferies presents the top drug innovations that investors ...
Read Full Story »
Stock Split Image

Biotech Giants Now Priced Like Old World Drug Stocks

Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are ...
Read Full Story »
DNA

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

The iShares Nasdaq Biotechnology (NASDAQ: IBB) exchange traded fund (ETF) has pulled back almost 17% since the February 25 peak, in a sell-off likened to the August 2011 debacle. Trading ...
Read Full Story »
76764023

Can MannKind Shares Double Again on FDA Approval? (Final)

MannKind Corp. (NASDAQ: MNKD) has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market for years, and that dream now seems ...
Read Full Story »
153576724

Vindication for MannKind With FDA Panel Backing

MannKind Corp. (NASDAQ: MNKD)had been trading as though the stock was bracing for an U.S. Food and Drug Administration (FDA) panel decision recommending against the approval of its inhalable insulin ...
Read Full Story »
biotech

Will Prana’s Implosion Go All the Way?

The first question anyone might ask if a stock falls from more than $9 to less than $2.50 is whether it already imploded? Prana Biotechnology Ltd. (NASDAQ: PRAN) has done ...
Read Full Story »
SupremeCourt

Teva’s Latest Victory in Effort to Protect Key Patents

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent that would protect ...
Read Full Story »
research

Biotech Firm Prana Misses Goal on Alzheimer Drug

Australia-based biotech firm Prana Biotechnology Ltd. (NASDAQ: PRAN) announced Monday morning that top-line results for a Phase II trial of its Alzheimer drug failed to meet its primary endpoint. Shares ...
Read Full Story »